Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial | JACC: Heart Failure
PDF) Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial
Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure | NEJM
PIONEER-HF (TIMI 62) – TIMI STUDY GROUP
![PDF] Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/d474228e511e7443caf668ac0e19b959a29bbe2d/4-Figure1-1.png "PDF] Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial | Semantic Scholar")
PDF] Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial | Semantic Scholar
Earlier Treatment Intervention in Heart Failure Patients Results in Improved Outcomes - The Medical Xchange
Abstract 13838: Efficacy and Safety of Sacubitril/Valsartan in Acute Decompensated Heart Failure in High-Risk Patients in the PIONEER-HF Trial | Circulation
Clinical Trial and Biomarker Data | ENTRESTO® (sacubitril/valsartan) | HCP
Clinical outcomes of Sacubitril/Valsartan in patients with acute heart failure: A multi-institution study - eClinicalMedicine
PIONEER-HF (TIMI 62) – TIMI STUDY GROUP
Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt‐pRo‐bnp in patients stabilized from an acute Heart Failure episode (PIONEER‐HF) trial | Semantic Scholar
Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial | JACC: Heart Failure
PIONEER-HF Supports Entresto as a First Choice Systolic Heart Failure Therapy | DAIC
![Thread by @FrailtyMD: " PIONEER-HF Trial: Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure pubmed.com/30415601 Double-blind RCT at […]" #Tweetorial](https://pbs.twimg.com/media/DzETnO0V4AA-oOP.jpg "Thread by @FrailtyMD: \" PIONEER-HF Trial: Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure pubmed.com/30415601 Double-blind RCT at […]\" #Tweetorial")
Thread by @FrailtyMD: " PIONEER-HF Trial: Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure pubmed.com/30415601 Double-blind RCT at […]" #Tweetorial
PDF) Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial
PIONEER HF Inclusion Exclusion Criteria - YouTube
Ingegneria d'urgenza - Dal New England Journal of Medicine: nei pazienti affetti da scompenso cardiaco, Il PARADIGM-HF trial e il PIONEER-HF trial hanno dimostrato una minore mortalità e una maggiore riduzione dell'NT-ProBNP
Angiotensin Receptor-Neprilysin Inhibition in Patients Hospitalized With Acute Decompensated Heart Failure
Frontiers | Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
Emerging Treatment Approaches to Improve Outcomes in Patients with Heart Failure | Cardiology Discovery
Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial | Circulation: Heart Failure
Nature Reviews Cardiology on Twitter: "Results of the PIONEER-HF trial: in patients with acute decompensated HF,sacubitril–valsartan led to greater reduction in NT-proBNP levels than enalapril. https://t.co/UyDY9cLco9" / Twitter
PARADISE MI Trial: Is Sacubitril/valsartan (Entresto) useful in patients with acute MI? – Visualmed
